[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 1951


Author Affiliations

From the ophthalmological service of Dr. R. Townley Paton, Manhattan Eye, Ear and Throat Hospital, New York.

AMA Arch Ophthalmol. 1951;46(4):419-420. doi:10.1001/archopht.1951.01700020430006

THE DRAMATIC suppression of certain inflammatory reactions by cortisone and corticotropin (ACTH) is now well known. In the search for effective substitutes for these drugs, numerous other substances have been subjected to clinical trial by various investigators. One of these is Δ5-pregnenolone (Δ5-pregnen-3-β-ol 20-one), usually referred to as pregnenolone, which is chemically related to the adrenal corticosteroids. Some published reports1 claim good therapeutic action in rheumatoid arthritis with this drug. This suggested the possibility that pregnenolone might be a readily available, easily administered, and nontoxic medication for uveitis, which usually responds well to cortisone and corticotropin.

Pregnenolone was given to 10 patients with various forms of uveal inflammation. This series consisted of one case each of the following diseases: recurrent exudative chorioretinitis, acute granulomatous uveitis with secondary glaucoma, malignant cyclitis following retinal detachment, chorioretinitis juxtapapillaris, granulomatous iridocyclitis associated with parotitis, recurrent nodular iritis, recurrent plastic

First Page Preview View Large
First page PDF preview
First page PDF preview